ERBB2 and breast cancer: The PHILA trial demonstrated a benefit in terms of PFS derived from the addition of pyrotinib to first-line trastuzumab + chemotherapy in patients with metastatic HER2-positive breast cancer; however, the increasing risk of gastrointestinal toxicity should be carefully assessed [72].